| Literature DB >> 17957245 |
Caitlin M Conboy1, Christiana Spyrou, Natalie P Thorne, Elizabeth J Wade, Nuno L Barbosa-Morais, Michael D Wilson, Arindam Bhattacharjee, Richard A Young, Simon Tavaré, Jacqueline A Lees, Duncan T Odom.
Abstract
Maintaining quiescent cells in G0 phase is achieved in part through the multiprotein subunit complex known as DREAM, and in human cell lines the transcription factor E2F4 directs this complex to its cell cycle targets. We found that E2F4 binds a highly overlapping set of human genes among three diverse primary tissues and an asynchronous cell line, which suggests that tissue-specific binding partners and chromatin structure have minimal influence on E2F4 targeting. To investigate the conservation of these transcription factor binding events, we identified the mouse genes bound by E2f4 in seven primary mouse tissues and a cell line. E2f4 bound a set of mouse genes that was common among mouse tissues, but largely distinct from the genes bound in human. The evolutionarily conserved set of E2F4 bound genes is highly enriched for functionally relevant regulatory interactions important for maintaining cellular quiescence. In contrast, we found minimal mRNA expression perturbations in this core set of E2f4 bound genes in the liver, kidney, and testes of E2f4 null mice. Thus, the regulatory mechanisms maintaining quiescence are robust even to complete loss of conserved transcription factor binding events.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17957245 PMCID: PMC2020443 DOI: 10.1371/journal.pone.0001061
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Strategy to compare E2F4 bound and E2F4 dependent gene expression in mouse and human.
(A) Transcription factor binding was identified in vivo using chromatin immunoprecipitation combined with proximal promoter arrays in three human tissues, a human cell line, seven mouse tissues, and a mouse cell line. (B) Gene expression in the liver, kidney, and testes of littermate mice lacking one or two copies of E2f4 were compared in replicate, and genes specifically perturbed in the adult identified in all three tissues. (C) Analysis approaches identified the genes bound in common among all human and all mouse tissues, those shared between species, and whether any genes were both bound by E2f4 in mouse adult liver, kidney, or testes, and whose expression were altered by removal of E2f4.
Figure 2Genome-wide binding of E2F4 in mouse and human tissues.
(A) Fraction of overlap of human genes bound by E2F4 in liver, pancreatic islets, pancreatic acinar, and HepG2 is shown as a grayscale shaded graph. Fractions and shading are calculated relative to the tissue with the fewest bound genes. The total number of binding targets for each tissue is shown in white boxes. (B) Similar plot for the overlap of mouse genes bound by E2f4 in liver, spleen, kidney, brain, testes, pancreatic islets, pancreatic acinar, and Min6. (C) Overlap between the mouse and human genes bound in common in all mouse and human tissues where homologs exist between the species. Consistent with previous results [23], the overlap is approximately 20%. (D) The genes bound by E2F4 in both mouse and human are substantially enriched in genes accounting for E2F4 function.
Functional categorization of genes bound commonly among human tissues.
| Selected genes (by category) bound by E2F4 in all human tissues | p-value for E2F4 binding | |||||
| Process | Gene | Full Name | Liver | Acinar | Islets | HepG2 |
|
| ZWINT | ZW10 interactor | 4.0E-08 | 6.0E-08 | 7.0E-08 | 4.0E-08 |
| (1×10–44) | CCNB1 | Cyclin B1 | 7.0E-08 | 9.0E-08 | 2.0E-07 | 8.0E-08 |
| INCENP | Inner centromere protein | 2.0E-07 | 3.0E-07 | 3.0E-07 | 2.0E-07 | |
| CDC23 | Cell division cycle 23 homolog | 2.0E-06 | 3.0E-06 | 3.0E-06 | 1.0E-06 | |
| CDC6 | Cell division cycle 6 homolog | 5.0E-08 | 7.0E-08 | 9.0E-08 | 5.0E-08 | |
| CDK2 | Cyclin-dependent kinase 2 | 4.0E-06 | 8.0E-06 | 5.0E-06 | 5.0E-06 | |
| NEK2 | NIMA-related kinase 2 | 2.0E-05 | 3.0E-05 | 2.0E-05 | 2.0E-05 | |
| MAD2L1 | MAD2 mitotic arrest deficient-like 1 | 5.0E-07 | 1.0E-06 | 9.0E-07 | 5.0E-07 | |
| CDC45L | CDC45 cell division cycle 45-like | 3.0E-07 | 5.0E-07 | 5.0E-07 | 3.0E-07 | |
| CCNB2 | Cyclin B2 | 2.0E-08 | 2.0E-08 | 3.0E-08 | 3.0E-08 | |
| RBL1 | Retinoblastoma-like 1 (p107) | 3.0E-06 | 4.0E-06 | 4.0E-06 | 3.0E-06 | |
| NUDC | Nuclear distribution gene C homolog | 3.0E-05 | 4.0E-05 | 3.0E-05 | 3.0E-05 | |
| E2F3 | E2F transcription factor 3 | 1.0E-05 | 1.0E-05 | 1.0E-05 | 1.0E-05 | |
| TCF19 | Transcription factor 19 (SC1) | 9.0E-07 | 2.0E-06 | 2.0E-06 | 7.0E-07 | |
| CCNG2 | Cyclin G2 | 1.0E-07 | 1.0E-07 | 2.0E-07 | 1.0E-07 | |
|
| RFC3 | Replication factor C (activator 1) 3 | 1.0E-06 | 2.0E-06 | 2.0E-06 | 9.0E-07 |
| (4×10–19) | PCNA | Proliferating cell nuclear antigen | 2.0E-06 | 3.0E-06 | 3.0E-06 | 2.0E-06 |
| POLE3 | Polymerase epsilon 3 (p17 subunit) | 2.0E-05 | 2.0E-05 | 2.0E-05 | 2.0E-05 | |
| NUP98 | Nucleoporin 98 kDa | 1.0E-05 | 2.0E-05 | 2.0E-05 | 2.0E-05 | |
| ORC3L | Origin recognition complex, subunit 3-like | 4.0E-07 | 5.0E-07 | 5.0E-07 | 3.0E-07 | |
| RRM1 | Ribonucleotide reductase M1 polypeptide | 2.0E-07 | 3.0E-07 | 3.0E-07 | 2.0E-07 | |
| ORC1L | Origin recognition complex, subunit 1-like | 7.0E-06 | 1.0E-05 | 1.0E-05 | 8.0E-06 | |
| TOP2A | Topoisomerase (DNA) II alpha | 8.0E-07 | 1.0E-06 | 1.0E-06 | 6.0E-07 | |
| RFC5 | Replication factor C (activator 1) 5 | 2.0E-06 | 4.0E-06 | 4.0E-06 | 2.0E-06 | |
| BLM | Bloom syndrome | 7.0E-09 | 6.0E-09 | 4.0E-09 | 6.0E-09 | |
|
| DCLRE1C | DNA cross-link repair 1C (PSO2 homolog) | 4.0E-07 | 6.0E-07 | 6.0E-07 | 4.0E-07 |
| (8×10–18) | XRCC1 | X-ray repair complementing defective repair | 5.0E-07 | 8.0E-07 | 7.0E-07 | 4.0E-07 |
| MLH1 | mutL homolog 1 | 2.0E-06 | 4.0E-06 | 4.0E-06 | 2.0E-06 | |
| BRCA1 | Breast cancer 1, early onset | 2.0E-07 | 2.0E-07 | 3.0E-07 | 2.0E-07 | |
| EXO1 | Exonuclease 1 | 6.0E-08 | 7.0E-08 | 1.0E-07 | 6.0E-08 | |
| TYMS | Thymidylate synthetase | 1.0E-07 | 1.0E-07 | 2.0E-07 | 1.0E-07 | |
| PMS2 | Postmeiotic segregation increased 2 | 4.0E-05 | 8.0E-05 | 6.0E-05 | 5.0E-05 | |
| FEN1 | Flap structure-specific endonuclease 1 | 7.0E-06 | 1.0E-05 | 1.0E-05 | 8.0E-06 | |
| NUDT1 | Nudix-type motif 1 | 4.0E-05 | 7.0E-05 | 5.0E-05 | 5.0E-05 | |
| RAD51 | RecA homolog | 1.0E-07 | 2.0E-07 | 2.0E-07 | 2.0E-07 | |
|
| NUDT2 | Nudix-type motif 2 | 2.0E-07 | 2.0E-07 | 1.0E-07 | 9.0E-08 |
| (6×10–6) | CASP8AP2 | CASP8 associated protein 2 | 2.0E-05 | 2.0E-05 | 2.0E-05 | 2.0E-05 |
| ITGB3BP | Integrin beta 3 binding protein | 1.0E-05 | 2.0E-05 | 2.0E-05 | 2.0E-05 | |
| TEGT | Testis enhanced gene transcript | 4.0E-05 | 6.0E-05 | 5.0E-05 | 3.0E-05 | |
| NDUFS1 | NADH dehydrogenase (ubiquinone) Fe-S 1 | 3.0E-06 | 4.0E-06 | 4.0E-06 | 3.0E-06 | |
| BNIP3L | BCL2/adenovirus E1B interacting protein 3-like | 4.0E-05 | 6.0E-05 | 5.0E-05 | 4.0E-05 | |
| SON | SON DNA binding protein | 4.0E-05 | 7.0E-05 | 5.0E-05 | 4.0E-05 | |
| CFL1 | Cofilin 1 (non-muscle) | 4.0E-05 | 6.0E-05 | 5.0E-05 | 3.0E-05 | |
| GLO1 | Glyoxalase I | 4.0E-08 | 6.0E-08 | 7.0E-08 | 4.0E-08 | |
| CHEK2 | CHK2 checkpoint homolog | 1.0E-08 | 8.0E-09 | 9.0E-09 | 1.0E-08 | |
|
| TTF2 | Transcription termination factor 2 | 2.0E-08 | 2.0E-08 | 3.0E-08 | 3.0E-08 |
| (4×10–8) | CSTF3 | Cleavage stimulation factor, subunit 3 | 3.0E-07 | 5.0E-07 | 5.0E-07 | 3.0E-07 |
| HSPC148 | Hypothetical protein HSPC148 | 1.0E-05 | 2.0E-05 | 2.0E-05 | 1.0E-05 | |
| SNRPF | Small nuclear ribonucleoprotein peptide F | 4.0E-05 | 6.0E-05 | 5.0E-05 | 4.0E-05 | |
| DIS3 | DIS3 mitotic control homolog | 4.0E-06 | 8.0E-06 | 6.0E-06 | 5.0E-06 | |
| SIP1 | survival interacting protein 1 | 3.0E-05 | 4.0E-05 | 4.0E-05 | 3.0E-05 | |
| FTSJ2 | FtsJ homolog 2 (E. coli) | 3.0E-06 | 4.0E-06 | 4.0E-06 | 3.0E-06 | |
| CSTF2T | cleavage stimulation factor, subunit 2, tau | 9.0E-07 | 2.0E-06 | 1.0E-06 | 7.0E-07 | |
| LSM3 | LSM3 homolog, U6 sn RNA associated | 2.0E-06 | 3.0E-06 | 3.0E-06 | 2.0E-06 | |
| SFRS1 | splicing factor, arginine/serine-rich 1 | 2.0E-07 | 2.0E-07 | 3.0E-07 | 2.0E-07 | |
Organized by GO categories, top hits by significance with p-values and binding ratios.
Figure 3Gene expression changes upon germline removal of E2f4 transcription factor binding in mouse liver, kidney, and testes are minimal, and poorly overlap the genes bound in mice containing E2f4.
(A) The complete list of genes that were differentially expressed when E2f4 was removed where the proximal promoter of these transcripts was present on the mouse promoter array. Genes were sorted by confidence in kidney, liver, and testes, sequentially, and the binding data then obtained separately. Most gene expression changes were tissue-specific, and very few of these genes showed in vivo E2f4 binding. (B) The complete list of genes bound by E2f4 in kidney, liver, and testes, clustered by transcription factor binding in each tissue sequentially. The transcripts of almost no genes bound in vivo were perturbed in the adult E2f4 null mice.